Altimmune (NASDAQ:ALT) Stock

ALTIMMUNE INC

Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Inc

AltLayer - United States Dollar

ALT11M2507 - United States Dollar

ALT11M250830 - United States Dollar

ALT11M251029 - United States Dollar

ALT2612 - United States Dollar

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTURAS MINERALS CORP by Alturas Minerals Corp.

Alturas Minerals Corp

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

ARCADIUM LITHIUM PLC SHS

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

ALTERA CORP COM

ALT5 Sigma Corp

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

Shares of Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 5.8% to $5.82 on Tuesday afternoon, despite no new company-specific news for the session. The biotech stock is trending on the social media platform Stocktwits, possibly fueled by high short interest and investor excitement over recent clinical trial developments.
What To Know: On Monday, Altimmune <a href="https://www.benzinga.com/pressreleases/25/05/g45490287/altimmune-announces-initiation-of-reclaim-phase-2-trial-evaluating-the-efficacy-and-safety-of-pemv">announced</a> it has enrolled the first subject in its RECLAIM Phase 2 trial evaluating pemvidutide for Alcohol Use Disorder. Pemvidutide, a dual GLP-1/glucagon receptor agonist, is also being studied for MASH, obesity, and Alcohol-Associated Liver Disease. 
RECLAIM will involve 100 subjects across 15 U.S. sites, with the primary endpoint focused on reducing heavy drinking days over 24 weeks.
According to data from <a href="https://www.benzinga.com/pro/register?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=8ImWZqfDzlXA">Benzinga Pro</a>, the stock has a short float of 22.58 million shares, representing 28.05% of float, indicating heavy short interest and potential for a short squeeze.
Altimmune's <a href="https://www.benzinga.com/pressreleases/25/05/g45490287/altimmune-announces-initiation-of-reclaim-phase-2-trial-evaluating-the-efficacy-and-safety-of-pemv">ongoing</a> Phase 2b trial in MASH is expected to deliver topline results in the second-quarter, with its ALD trial set to begin enrollment in the third-quarter.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45521011/short-seller-targets-archer-aviation-stock-extends-wager-to-tonight-show-host-jimmy-fallon-reckless-promotion">Short Seller Targets Archer Aviation Stock, Extends Wager To &#8216;Tonight Show&#8217; Host Jimmy Fallon — &#8216;Reckless&#8217; Promotion</a>
<h2 class="wp-block-heading">How To Buy ALT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Altimmune&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, ALT has a 52-week high of $11.16 and a 52-week low of $3.55.
Photo: Shutterstock

News

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025.
RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025.

Altimmune Begins Phase 2 Trial of Pemvidutide for Alcohol Use Disorder With First Patient Enrolled

Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.
 &nbsp;

Financing

Altimmune Secures Up To $100M In Credit Facility From Hercules Capital

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 27.78 percent. This is a 23.53 percent increase over losses of $(0.34) per share from the same period last year. The company reported $5.00 thousand in sales this quarter. This is the same as the same period last year.

Earnings

Earnings Beats

Altimmune Q1 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.00K, Same YoY, Cash And Equivalents $150M

ABOS

ABSI

ACCS

ACHV

ACXP

ADAP

ALCO

ALLO

ASNS

AUID

AVXL

BDSX

BEAT

BKTI

BWAY

BWEN

CAMT

CAPR

CINT

CLPT

CLRB

CNCK

CYBR

DARE

DLPN

DMAC

ELMD

ETON

EXEL

FENC

FLOC

FTHM

GAIN

GAUZ

GENK

GEVO

GNSS

GOCO

GRAL

GUTS

HSON

HUMA

HUYA

HYFM

HYLN

HYPR

ICMB

IMOS

INLX

IRIX

ITRM

IZEA

KOPN

KRMN

LCTX

LEGN

LOAR

LSTR

LUNR

LXRX

MASS

MBRX

MCHX

MDAI

MGNX

MPTI

NMTC

NPCE

NUTX

NUWE

NXGL

NYAX

OKLO

ONON

OPXS

PERI

PRTS

PSFE

PXLW

Earnings Scheduled For May 13, 2025

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Altimmune to report an earnings per share (EPS) of $-0.34.
The announcement from Altimmune is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.01 in the last quarter, leading to a 3.58% increase in the share price on the following day.
Here's a look at Altimmune's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.35</td>
<td>-0.34</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.33</td>
<td>-0.32</td>
<td>-0.35</td>
<td>-0.34</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747083702_0.png" alt="eps graph" />
<h3>Market Performance of Altimmune's Stock</h3>
Shares of Altimmune were trading at $5.59 as of May 09. Over the last 52-week period, shares are down 23.15%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Insights on Altimmune</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Altimmune.
A total of 5 analyst ratings have been received for Altimmune, with the consensus rating being Buy. The average one-year price target stands at $17.2, suggesting a potential 207.69% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Sage Therapeutics, Precigen and Organogenesis Holdings, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Sage Therapeutics, with an average 1-year price target of $9.5, suggesting a potential 69.95% upside.</li>
<li>Analysts currently favor an Buy trajectory for Precigen, with an average 1-year price target of $6.0, suggesting a potential 7.33% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Organogenesis Holdings, with an average 1-year price target of $6.0, suggesting a potential 7.33% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for Sage Therapeutics, Precigen and Organogenesis Holdings are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeiraGTx Hldgs</td>
<td>Buy</td>
<td>948.53%</td>
<td>$9.58M</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Sage Therapeutics</td>
<td>Neutral</td>
<td>77.97%</td>
<td>$13.41M</td>
<td>-14.22%</td>
</tr>
<tr>
<td>Precigen</td>
<td>Buy</td>
<td>-3.09%</td>
<td>$21K</td>
<td>-42.02%</td>
</tr>
<tr>
<td>Organogenesis Holdings</td>
<td>Neutral</td>
<td>27.10%</td>
<td>$95.61M</td>
<td>2.17%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Altimmune is positioned at the bottom for Revenue Growth, with a significant negative percentage compared to its peers. In terms of Gross Profit, Altimmune is also at the bottom with the lowest figure among the group. However, Altimmune's Return on Equity is higher than some peers, placing it in the middle for this metric. Overall, Altimmune's performance is weaker in terms of Revenue Growth and Gross Profit compared to its peers.
<h3>Delving into Altimmune's Background</h3>
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
<h3>Altimmune: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Altimmune's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -86.49%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Altimmune's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -463600.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.05%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Altimmune's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.14%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Altimmune adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/ALT/earnings">To track all earnings releases for Altimmune visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Altimmune's Earnings

<a href="https://www.globenewswire.com/Tracker?data=ByQ0hAqMA-BFwHQ_c9wwUwivhSBvctYECkfqucmDzRi624_OCF6QcetLLhtOMTxF7nVplwYavWeiHwvNFfQhdA==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the presentation of new analyses at the European Association for the Study of the Liver (EASL) Congress&#x2122; in&nbsp;Amsterdam, The Netherlands. The presentation focuses on the use of the MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution on biopsy in patients treated with pemvidutide, Altimmune's 1:1 GLP-1/glucagon dual receptor agonist.

Altimmune Announces Presentation Of New Analyses Predicting High Rates of MASH Resolution On Biopsy Following Pemvidutide Treatment At EASL International Liver Congress

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$42.00</td>
<td>$31.6K</td>
<td>1.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>ALDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.50</td>
<td>$62.2K</td>
<td>973</td>
<td>2.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$83.00</td>
<td>$187.0K</td>
<td>24</td>
<td>1.0K</td>
</tr>
<tr>
<td>KNSA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$20.00</td>
<td>$42.7K</td>
<td>308</td>
<td>299</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>5.0K</td>
<td>286</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.00</td>
<td>$30.0K</td>
<td>5.1K</td>
<td>200</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$72.50</td>
<td>$31.9K</td>
<td>2.7K</td>
<td>197</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$77.4K</td>
<td>29.7K</td>
<td>115</td>
</tr>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$27.1K</td>
<td>434</td>
<td>104</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$480.00</td>
<td>$50.9K</td>
<td>849</td>
<td>63</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bullish, expiring in 4 day(s) on May 9, 2025. This event was a transfer of 80 contract(s) at a $42.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $395.0 per contract. There were 1486 open contracts at this strike prior to today, and today 3666 contract(s) were bought and sold. 
• For ALDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 1778 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $62.2K, with a price of $35.0 per contract. There were 973 open contracts at this strike prior to today, and today 2028 contract(s) were bought and sold. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on May 23, 2025. Parties traded 1000 contract(s) at a $83.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $187.0K, with a price of $187.0 per contract. There were 24 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• Regarding KNSA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), we observe a call option sweep with bullish sentiment. It expires in 74 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $20.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $42.7K, with a price of $855.0 per contract. There were 308 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bullish, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 79 contract(s) at a $80.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $520.0 per contract. There were 5034 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a call option trade that happens to be bearish, expiring in 137 day(s) on September 19, 2025. This event was a transfer of 200 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $150.0 per contract. There were 5132 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be neutral, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 49 contract(s) at a $72.50 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $658.0 per contract. There were 2748 open contracts at this strike prior to today, and today 197 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a put option sweep with bullish sentiment. It expires in 256 day(s) on January 16, 2026. Parties traded 113 contract(s) at a $30.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $77.4K, with a price of $686.0 per contract. There were 29726 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• For CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 28 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $970.0 per contract. There were 434 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on May 16, 2025. Parties traded 7 contract(s) at a $480.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $50.9K, with a price of $7280.0 per contract. There were 849 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INSM

KNSA

10 Health Care Stocks Whale Activity In Today's Session

Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares jumped 8.5% to $5.61 on Friday, ahead of <a href="https://www.benzinga.com/pressreleases/25/05/g45130957/altimmune-to-present-at-upcoming-easl-international-liver-congress-2025">next week&#8217;s presentation</a> at the European Association for the Study of the Liver International Liver Congress 2025. The stock also trended on Stocktwits as investor interest surged.
What To Know: The Maryland-based biopharma company will present analyses of its investigational drug pemvidutide in treating metabolic dysfunction-associated steatotic liver disease. The company says the data leverages the novel MASH Resolution Index, a non-invasive metric that predicts histologic improvements in liver health. 
Altimmune's findings will be shared in <a href="https://www.benzinga.com/pressreleases/25/05/g45130957/altimmune-to-present-at-upcoming-easl-international-liver-congress-2025">two poster sessions</a> during the congress in Amsterdam, including a guided tour on May 8 and a general session on May 10.
Dr. Shaheen Tomah, Director of Clinical Development, will present the results, as investors will be watching for meaningful advancements in non-invasive liver disease assessment.
Read Also: <a href="https://www.benzinga.com/25/05/45168400/apple-stock-falls-after-cook-warns-of-900m-tariff-impact">Apple Stock Falls After Cook Warns of $900M Tariff Impact</a>
<h2 class="wp-block-heading">How To Buy ALT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Altimmune&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALT has a 52-week high of $11.16 and a 52-week low of $3.56.

What's Going On With Altimmune (ALT) Stock Today?

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>),&nbsp;&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stocks are trading higher on Monday.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it&#8217;s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with weekly injections.
Eli Lilly is developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026. This would give Eli Lilly a two-year lead <a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">before rivals catch up</a>.
In March, Viking Therapeutics completed subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company&#8217;s dual agonist of the GLP-1 and glucose-dependent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44490486/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-oral-dosing-trial-of-vk2" rel="noreferrer noopener">insulinotropic polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for various metabolic disorders, such as obesity. Viking expects to report data from the study in <a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">the second half of 2025</a>.
Viking plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025.
In June 2024, Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) unveiled 12-week topline obesity data from its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39144875/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforgli" target="_blank" rel="noreferrer noopener">Phase 2a study of GSBR-1290</a>.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39133591/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-t" rel="noreferrer noopener">6.2% at 12 weeks</a>.&nbsp;
In July 2024, Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39812408/roche-highlights-encouraging-data-from-newly-acquired-second-weight-loss-drug-candidate-in-early-" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
This data is better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>.
In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit" rel="noreferrer noopener">transaminases (liver enzymes)</a>.
In March, Altimmune Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) unveiled the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments&nbsp;for its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">obesity drug, pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Price Action: LLY stock is up 1.14% at $739.26, NVO stock is up 1.68% at $65.82, ALT stock is up 3.40% at $4.56, VKTX stock is up 13.5% at $25.21
GPCR stock is up 8.36% at $17.23 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44788755/bp-discovers-oil-at-far-south-prospect-in-deepwater-gulf-boosts-upstream-growth-outlook" target="_blank" rel="noreferrer noopener">BP Discovers Oil At Far South Prospect in Deepwater Gulf, Boosts Upstream Growth Outlook</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

Trading Ideas

General

GPCR

RHHBY

VKTX

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Altimmune, revealing an average target of $16.0, a high estimate of $25.00, and a low estimate of $12.00. Observing a 1.85% increase, the current average has risen from the previous average price target of $15.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1743703213_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Altimmune's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Altimmune. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Altimmune's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Altimmune</h2>
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
<h3>Financial Milestones: Altimmune's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Altimmune's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -86.49% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Altimmune's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -463600.0%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Altimmune's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.05%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Altimmune's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.14%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

8 Analysts Assess Altimmune: What You Need To Know

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

Citizens Capital Markets analyst Jonathan Wolleben reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Market Outperform and maintains $25 price target.

Citizens Capital Markets Reiterates Market Outperform on Altimmune, Maintains $25 Price Target

WIIM

Altimmune shares are trading higher amid rumours several large pharmaceutical organizations are interested in the company.

Rumors

Watching Altimmune; Traders Circulate M&A Blog Comments Suggesting Multiple Large Pharma Co's Interested In The Company

Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) hosted a virtual R&amp;D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">for pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Altimmune <a href="https://investorday.altimmune.com/presentation" target="_blank" rel="noreferrer noopener">anticipates</a> pemvidutide will reduce alcohol cravings, improve liver health and promote weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>
<ul>
<li>The primary <a href="https://investorday.altimmune.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" target="_blank" rel="noreferrer noopener">endpoint</a> for the Phase 2 ALD study will be a change in liver stiffness measurement at 24 weeks, with other key endpoints of weight loss and change in alcohol consumption, with an additional <a href="https://www.benzinga.com/news/24/06/39456224/altimmune-stock-is-rising-monday-whats-driving-the-action" target="_blank" rel="noreferrer noopener">reading at 48 weeks</a>.</li>
<li>The primary endpoint of the Phase 2 AUD study will be the change in the number of heavy drinking days at 24 weeks and the change in biomarkers of alcohol consumption and weight loss as secondary endpoints.</li>
</ul>
William Blair writes, &#8220;In our view, AUD and ALD are logical extensions for evaluation of pemvidutide&#8217;s efficacy, given its mechanisms of action.&#8221;
Altimmune shared the MOMENTUM Phase 2 trial data summary during the presentation, showing that over 30% of subjects lost ≥ 20% of body weight on pemvidutide 2.4 mg dose.
<ul>
<li>The lean mass ratio of lean body mass weight loss to total weight loss was 21.9% for pemvidutide in the Phase 2 MOMENTUM study, compared to 39.9% for semaglutide (based on Phase 3 STEP-1 trial data), 37.7% for retatrutide (from the Phase 2 study), and 26% for tirzepatide in the Phase 3 SURMOUNT 1 trial.</li>
</ul>
Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic and Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is available as Zepbound and Mounjaro.
The company says Phase 2b IMPACT trial results of pemvidutide for MASH are expected in the second quarter, and if successful, pemvidutide would become:
<ul>
<li>The first incretin-based agent to achieve statistical significance on fibrosis improvement at 24 weeks.</li>
<li>The first therapeutic candidate in any class to achieve statistically significant fibrosis improvement and meaningful weight loss at 24 weeks.</li>
<li>Altimmune expects to start registrational Phase 3 study in MASH in the first half of 2026</li>
</ul>
The presentation highlighted that at 24 weeks in the Phase 1b trial in metabolic dysfunction-associated steatotic liver disease (MASLD), pemvidutide demonstrated a 76.4% relative reduction in liver fat at the highest 2.4 mg dose (compared to 14% for placebo).
ALT Price Action: ALT stock is up 4.71% at $5.45 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44312852/needham-downgrades-dental-players-dentsply-sirona-zimvie-citing-weak-growth-outlook" target="_blank" rel="noreferrer noopener">Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst</a></li>
</ul>
Photo: Shutterstock

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders

Ratings for Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.5, a high estimate of $18.00, and a low estimate of $12.00. This current average has increased by 12.5% from the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741035645_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Altimmune by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Altimmune. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Altimmune's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Altimmune's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Altimmune Better</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>A Deep Dive into Altimmune's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Altimmune's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -98.62%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Altimmune's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -456900.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -15.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Altimmune's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.22%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Press Releases

Altimmune to Participate in the Leerink Global Healthcare Conference

Altimmune to Host Virtual R&D Day on March 13, 2025

Altimmune to Participate in the Citizens Life Sciences Conference

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Comments

Altimmune

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL